CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3479-3488

  Yamamoto, Makoto ^a,b,c   Onogi, Hiroshi ^b   Kii, Isao ^c   Yoshida, Suguru ^a   Iida, Kei ^c   Sakai, Hiroyuki ^c   Abe, Minako ^a   Tsubota, Toshiaki ^c   Ito, Nobutoshi ^a   Hosoya, Takamitsu ^a   Hagiwara, Masatoshi ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KinoPharma   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLIN DEPENDENT KINASE 9 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; FIT 039; FLAVOPIRIDOL; FLT 039; MESSENGER RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CDK9 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 9; DNA VIRUS; FIT-039; FLAVONOID; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DNA VIRUS; DRUG EFFECT; DRUG MECHANISM; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MALE; MOUSE; NONHUMAN; OINTMENT; PRIORITY JOURNAL; RAT; SKIN DEFECT; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHEMISTRY; CYTOMEGALOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HERPES SIMPLEX; HOST PATHOGEN INTERACTION; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOLOGY; PHYSIOLOGY; TOXICITY; VIROLOGY; WISTAR RAT;

ACYCLOVIR; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; CYCLIN-DEPENDENT KINASE 9; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; DNA VIRUSES; DRUG RESISTANCE, VIRAL; FLAVONOIDS; HEK293 CELLS; HELA CELLS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, INBRED ICR; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, WISTAR; TRANSCRIPTION, GENETIC; TRANSCRIPTOME; VIRUS REPLICATION;

EID: 84905455016     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73805     Document Type: Article

References (49)

1. Ostertag W, et al. Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc Natl Acad Sci U S A. 1974;71(12):4980-4985.
2. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977;74(12):5716-5720.
3. Sellar RS, Peggs KS. Management of multidrugresistant viruses in the immunocompromised host. Br J Haematol. 2012;156(5):559-572.
4. Field HJ. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin Virol. 2001;21(3):261-269.
5. Wang Y, Wang Q, Zhu Q, Zhou R, Liu J, Peng T. Identification and characterization of acyclovirresistant clinical HSV-1 isolates from children. J Clin Virol. 2011;52(2):107-112.
6. Karlas A, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature. 2010;463(7282):818-822.
7. Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother. 2002;50(6):779-792.
8. Siakallis G, Spandidos DA, Sourvinos G. Herpesviridae and novel inhibitors. Antivir Ther. 2009;14(8):1051-1064.
9. Kusano-Kitazume A, et al. Identification of novel N-(morpholine-4- carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. Antimicrob Agents Chemother. 2012;56(3):1315-1323.
10. Anwar A, et al. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly. Plos One. 2011;6(8):e23246.
11. Karakama Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-argininerich protein kinase. Antimicrob Agents Chemother. 2010;54(8):3179-3186.
12. Fukuhara T, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006;103(30):11329-11333.
13. Van Duyne R, et al. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol. 2013;425(4):812-829.
14. Kapasi AJ, Clark CL, Tran K, Spector DH. Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription. J Virol. 2009;83(11):5904-5917.
15. Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother. 2006;17(6):293-320.
16. Tan SL, Ganji G, Paeper B, Proll S, Katze MG. Systems biology and the host response to viral infection. Nat Biotechnol. 2007;25(12):1383-1389.
17. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-166.
18. Kohoutek J, Blazek D. Cyclin K goes with Cdk12 and Cdk13. Cell Div. 2012;7:12.
19. Evers DL, Breitenbach JM, Borysko KZ, Townsend LB, Drach JC. Inhibition of cyclindependent kinase 1 by purines and pyrrolo[2, 3-d] pyrimidines does not correlate with antiviral activity. Antimicrob Agents Chemother. 2002;46(8):2470-2476.
20. Feichtinger S, et al. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1. J Gen Virol. 2011;92(pt 7):1519-1531.
21. Rechter S, et al. Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J Biol Chem. 2009;284(13):8605-8613.
22. Durand LO, Roizman B. Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol. 2008;82(21):10591-10599.
23. Biglione S, et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology. 2007;4:47.
24. Ou M, Sandri-Goldin RM. Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription. PLoS One. 2013;8(10):e79007.
25. Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P. A structural perspective of CTD function. Genes Dev. 2005;19(12):1401-1415.
26. Sanchez V, et al. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J Virol. 2004;78(20):11219-11232.
27. Schang LM, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wildtype and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol. 2002;76(15):7874-7882.
28. Delehouze C, et al. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells [published online ahead of print December 9, 2013]. Oncogene. doi:10.1038/onc.2013.513.
29. Thomas JP, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol. 2002;50(6):465-472.
30. Diwan P, Lacasse JJ, Schang LM. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoterspecific factors. J Virol. 2004;78(17):9352-9365.
31. Simmons A, Nash AA. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J Virol. 1984;52(3):816-821.
32. Betz UA, Fischer R, Kleymann G, Hendrix M, Rubsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primasehelicase inhibitor BAY 57-1293. Antimicrob Agents Chemother. 2002;46(6):1766-1772.
33. Vijayalingam S, Chinnadurai G. Adenovirus L-E1A activates transcription through mediator complex-dependent recruitment of the super elongation complex. J Virol. 2013;87(6):3425-3434.
34. Konig R, et al. Human host factors required for influenza virus replication. Nature. 2010;463(7282):813-817.
35. Nguyen DG, Wolff KC, Yin H, Caldwell JS, Kuhen KL. "UnPAKing" human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol. 2006;80(1):130-137.
36. Bakre A, et al. Identification of host kinase genes required for influenza virus replication and the regulatory role of microRNAs. PLoS One. 2013;8(6):e66796.
37. Cheng F, et al. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog. 2009;5(3):e1000324.
38. Lee JH, Yedavalli VR, Jeang KT. Activation of HIV-1 expression and replication by cGMP dependent protein kinase type 1-β (PKG1β). Retrovirology. 2007;4:91.
39. Coito C, Diamond DL, Neddermann P, Korth MJ, Katze MG. High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J Virol. 2004;78(7):3502-3513.
40. Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009;90(pt 8):1869-1879.
41. Jamaluddin M, Tian B, Boldogh I, Garofalo RP, Brasier AR. Respiratory syncytial virus infection induces a reactive oxygen species-MSK1-phospho-Ser-276 RelA pathway required for cytokine expression. J Virol. 2009;83(20):10605- 10615.
42. Hsu MJ, Hung SL. Antiherpetic potential of 6-bromoindirubin-3'-acetoxime (BIO-acetoxime) in human oral epithelial cells. Arch Virol. 2013;158(6):1287- 1296.
43. Guendel I, et al. Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol. 2014;88(2):1189-1208.
44. Zhang J, Li G, Ye X. Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J Virol. 2010;84(24):12619-12627.
45. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Mol Cell Biol. 1999;19(7):4592-4599.
46. Wang S, Zhang J, Ye X. [Protein kinase inhibitor flavopiridol inhibits the replication of influenza virus in vitro]. Wei Sheng Wu Xue Bao. 2012;52(9):1137-1142.
47. Ali A, et al. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem. 2009;10(12):2072-2080.
48. Mancebo HS, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 1997;11(20):2633-2644.
49. Zhu Y, et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 1997;11(20):2622-2632.